[1] SINHA G. Downfall of iniparib: a PARP inhibitor that doesn’t inhibit PARP after all.[J]. JNCI Journal of the National Cancer Institute, 2014, 106 1: djt447. DOI:
10.1093/jnci/djt447[2] JOAQUIN MATEO. Appraising iniparib, the PARP inhibitor that never was—what must we learn[J]. Nature Reviews Clinical Oncology, 2013, 10 12: 688-696. DOI:
10.1038/nrclinonc.2013.177[3] WENJIAN MA. Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109 17: 6590-6595. DOI:
10.1073/pnas.1118078109[4] XUESONG LIU. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.[J]. Clinical Cancer Research, 2012, 18 2: 510-523. DOI:
10.1158/1078-0432.ccr-11-1973